Risk of declining prices due to revisions to reimbursement points
First written in FY2016. 13 of 24 entries say "Restated". Latest entry: 2026-11-11.
The whole theme swung hardest in 2026: 7 of 17 companies on the "Worse" side.
8 other companies' latest entry also says "Restated".
- FY2026MitigatedAnnual report
「Although this is not a fiscal year in which reimbursement rates are revised, as such revisions are conducted every 2 years, and there was no reduction in reimbursement rates for laboratory tests, business conditions remain challenging due to rising costs of various kinds and the increasing burden of securing personnel amid labor shortages.」
As there was no reduction in reimbursement rates for laboratory tests in the current fiscal year, no price decline resulting from the revision occurred. However, rising costs and the burden of securing personnel continue. - FY2025RestatedAnnual report
「These reimbursement points are customarily revised by the Ministry of Health, Labour and Welfare every 2 years under the Health Insurance Act. If changes to the reimbursement system or reductions in rates charged to medical institutions are implemented as measures to contain national medical expenditure, the resulting impact on the prices at which our group performs tests under contract could affect our operating results and financial condition.」
The risk of declines in contract prices resulting from reimbursement-point revisions every 2 years and changes to the reimbursement system is reiterated. - FY2025-H1MaterialisedAnnual report
「Against this economic backdrop, 2024 is a fiscal year in which medical reimbursement rates are revised every 2 years. In addition to lower medical reimbursement rates for specimen testing, the business environment remains challenging because labor and other costs are rising and competition among providers continues.」
We reconfirm that reimbursement rates for laboratory tests were reduced in the reimbursement-rate revision year. - FY2024-Q3RestatedAnnual report
「Although this is not a fiscal year in which reimbursement rates are revised, as such revisions are conducted every 2 years, and there was no reduction in reimbursement points (official prices) for laboratory tests, business conditions remain challenging due to the decline in the number of COVID-19-related tests and continued competition among providers.」
We reconfirm that this quarter was not a reimbursement-rate revision year and that there was no reduction in reimbursement points for laboratory tests. However, competition and the decline in COVID-19 testing volumes continue. - FY2024-Q1MitigatedAnnual report
「Although this is not a fiscal year in which reimbursement rates are revised, as such revisions are conducted every 2 years, and there was no reduction in reimbursement points for laboratory tests, business conditions remain challenging due to continued competition among providers.」
As this quarter is not a reimbursement-rate revision year and there was no reduction in reimbursement points for laboratory tests, the risk of price declines from reimbursement-point revisions has not temporarily materialized. However, competition continues. - FY2023-Q3MaterialisedAnnual report
「Although the number of existing tests performed under contract increased, both revenue and profit declined due to the impact of lower reimbursement rates for COVID-19-related testing.」
The reduction in reimbursement rates for COVID-19-related testing continues to materialize as declines in revenue and profit, despite the increase in the number of existing tests performed under contract. - FY2023-Q2MaterialisedAnnual report
「Although the number of existing tests performed under contract increased, both revenue and profit declined due to the impact of lower reimbursement rates for COVID-19-related testing.」
Despite the increase in the number of existing tests performed under contract, the reduction in reimbursement rates for COVID-19-related testing continues to materialize as declines in revenue and profit. - FY2023-Q1MaterialisedAnnual report
「Although the total number of contracted tests increased, both revenue and profit declined due to the impact of lower medical reimbursement rates for COVID-19-related tests.」
The reduction in medical reimbursement rates for COVID-19-related tests actually resulted in lower revenue and profit despite an increase in the number of contracted tests. - FY2022-Q3RestatedAnnual report
「During the cumulative third quarter of the fiscal year, there were no material changes in the financial position, operating results, or cash flow situation, including any abnormal fluctuations, or in the business and other risks described in the annual securities report for the previous fiscal year. There were also no material events or other matters of concern.」
States that there have been no material changes to the risk of price declines due to reimbursement point revisions described in the previous fiscal year. - FY2020-Q3RestatedAnnual report
「During the cumulative third quarter of the fiscal year, there were no material changes in the financial position, operating results, or cash flow situation, including any abnormal fluctuations, or in the business and other risks described in the annual securities report for the previous fiscal year. There were also no material events or other matters of concern.」
States that there have been no material changes to the risk of price declines due to reimbursement point revisions described in the previous fiscal year. - FY2019RestatedAnnual report
「These reimbursement points are customarily revised every 2 years by the Ministry of Health, Labour and Welfare under the Health Insurance Act. If changes to the medical reimbursement system or reductions in the rates paid to medical institutions are implemented as measures to curb national healthcare expenditure, they could affect the Group’s operating results and financial position through their impact on contract prices.」
Continues to identify the impact on contract prices of reimbursement point revisions every 2 years, changes to the medical reimbursement system and reductions in rates as risks. - FY2019-Q3RestatedAnnual report
「Various healthcare system reforms are being implemented in the contract clinical testing industry to curb rising national healthcare expenditure. This fiscal year is one in which medical reimbursement rates, revised every 2 years, are being reviewed. Although reimbursement points for medical care as a whole were raised, those for specimen testing were reduced.」
Reiterates the fact that reimbursement points for specimen testing were reduced as a result of the medical reimbursement rate revision. - FY2019-Q2RestatedAnnual report
「Various healthcare system reforms are being implemented in the contract clinical testing industry to curb rising national healthcare expenditure. This fiscal year is one in which medical reimbursement rates, revised every 2 years, are being reviewed. Although reimbursement points for medical care as a whole were raised, those for specimen testing were reduced.」
Reiterates the fact that reimbursement points for specimen testing were reduced as a result of the medical reimbursement rate revision. quantified is false and materialized is true. - FY2019-Q1MaterialisedAnnual report
「This fiscal year is one in which medical reimbursement rates, revised every 2 years, are being reviewed. Although reimbursement points for medical care as a whole were raised, those for specimen testing were reduced.」
The reimbursement point reduction for specimen testing actually occurred as a result of the medical reimbursement rate revision. - FY2018-Q3RestatedAnnual report
「The contract clinical testing industry is not in a fiscal year in which medical reimbursement rates are revised every 2 years. Although there was no reduction in the reimbursement points for specimen testing (official prices), the business environment remains challenging because competition among providers continues.」
Although there was no reduction in reimbursement points for specimen testing in the quarter, competition among providers continues. - FY2018-Q2RestatedAnnual report
「Although this is not a fiscal year in which medical reimbursement rates are revised every 2 years and there was no reduction in the reimbursement points for specimen testing (official prices), the business environment remains challenging because competition among providers continues.」
Although there was no reduction in reimbursement points in the quarter and no price decline due to the revision was observed, competition among providers continues. - FY2018-Q1MitigatedAnnual report
「Although this is not a fiscal year in which medical reimbursement rates are revised every 2 years and there was no reduction in the reimbursement points for specimen testing (official prices), the business environment remains challenging because competition among providers continues.」
Because there was no reduction in reimbursement points for specimen testing in the quarter, the risk of price declines due to reimbursement point revisions has not materialized. However, competition among providers continues. - FY2017RestatedAnnual report
「These reimbursement points are customarily revised every 2 years by the Ministry of Health, Labour and Welfare under the Health Insurance Act. If changes to the medical reimbursement system or reductions in the rates paid to medical institutions are implemented as measures to curb national healthcare expenditure, they could affect the Group’s operating results and financial position through their impact on contract prices.」
Continues to identify the impact on contract prices of reimbursement point revisions every 2 years, changes to the medical reimbursement system and reductions in rates as risks. - FY2017-Q3RestatedAnnual report
「The contract clinical testing industry is in a fiscal year in which medical reimbursement rates, revised every 2 years, are being reviewed. Although there was no significant overall reduction in the reimbursement points for specimen testing, the business environment remains challenging because competition among providers continues.」
Continues to state that the current year’s revision of medical reimbursement rates did not result in a significant overall reduction in reimbursement points for specimen testing. - FY2017-Q2RestatedAnnual report
「The contract clinical testing industry is in a fiscal year in which medical reimbursement rates, revised every 2 years, are being reviewed. Although there was no significant overall reduction in the reimbursement points for specimen testing, the business environment remains challenging because competition among providers continues.」
Continues to state that the current year’s revision of medical reimbursement rates did not result in a significant overall reduction in reimbursement points for specimen testing. - FY2017-Q1MitigatedAnnual report
「This fiscal year is one in which medical reimbursement rates, revised every 2 years, are being reviewed. Although there was no significant overall reduction in the reimbursement points for specimen testing, the business environment remains challenging because competition among providers continues.」
States that the current year’s revision of medical reimbursement rates did not result in a significant overall reduction in reimbursement points for specimen testing. However, competition among providers continues. - FY2016First statedAnnual report
「These reimbursement points are customarily revised every 2 years by the Ministry of Health, Labour and Welfare under the Health Insurance Act. If changes to the medical reimbursement system or reductions in the rates paid to medical institutions are implemented as measures to curb national healthcare expenditure, they could affect the Group’s operating results and financial position through their impact on contract prices.」
In light of reimbursement points being revised every 2 years, identifies changes to the medical reimbursement system and reductions in rates as risks.